IP Library Granted Patent US 9,034,087
Granted Patent B2
US 9,034,087 · App. 14/201,629 · Granted May 19, 2015

Ink formulation and manufacture thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,034,087
App. No.
14/201,629
Granted
May 19, 2015
Kind
B2
Abstract

An ink formulation for marking living tissue comprises a dispersion of carbon black pigment particles encapsulated in water soluble shells, mixed with a pharmaceutically accepted carrier, such as water, and a preservative. A dispersion formulation is preferential to a suspension formulation for marking living tissue because the carbon particles of the dispersion formulation are less likely to aggregate and sediment over time. In addition, the absence of large quantities of additives makes a dispersion formulation less reactive to living tissue, further enhancing its appeal as a biological marker.

Claims (24)

1. An ink formulation for use on living tissue, having a total weight, comprising

a pharmaceutically acceptable carrier;

a preservative; and

carbon pigment, wherein said carbon pigment is in a range of 1.09% to 1.10% of the total weight, wherein particles of said carbon pigment are encapsulated by at least one of lecithin, soy lecithin, polyvinylpyrrolidone (PVP), emulsifying wax, polysorbate 20, or glycerin to form a water-soluble coating around said carbon pigment particles, and wherein said ink formulation is a dispersion of said preservative and carbon pigment in the carrier.

2. The ink formulation of claim 1 wherein the preservative is one of 2-phenoxyethanol, benzyl alcohol, methyl/propyl paraben blend, or polyaminopropyl biguanide.

3. The ink formulation of claim 1 wherein the formulation does not include suspending agents, viscosity agents, surfactants, ceteareth 20, or antifoaming agents.

4. The ink formulation of claim 1 , wherein said ink formulation is made by:

mixing the pharmaceutically accepted carrier with the preservative to form a carrier-preservative compound;

pre-wetting the carbon pigment with a first emulsifying agent, wherein the first emulsifying is at least one of lecithin, soy lecithin, polyvinylpyrrolidone (PVP), emulsifying wax, polysorbate 20, or glycerin to form pre-wet carbon;

mixing a second emulsifying agent with glycerin to form an emulsifier-glycerin compound;

adding said emulsifier-glycerin compound to the pre-wet carbon and mixing until encapsulated carbon particles are formed; and

mixing said carrier-preservative compound with said encapsulated carbon particles to form said ink formulation.

5. The ink formulation of claim 1 , wherein said pharmaceutically accepted carrier is water.

6. The ink formulation of claim 5 , wherein said water comprises approximately 91.73% of the total formulation by weight.

7. The ink formulation of claim 1 , wherein said preservative comprises approximately 1.24% of the total formulation by weight.

8. The ink formulation of claim 1 , wherein said carbon pigment is carbon black and the carbon black contains PAH in a range of 0.5 ppm or more.

9. The ink formulation of claim 8 , wherein said carbon black comprises between 1.09 and 1.10% of the total formulation by weight.

10. The ink formulation of claim 8 , wherein said carbon black comprises substantially 1.09% of the total formulation by weight.

11. The ink formulation of claim 4 , wherein said second emulsifying agents are selected from the group consisting of lecithin, soy lecithin, PVP, emulsifying wax, and polysorbate 20.

12. The ink formulation of claim 4 , wherein said first and second emulsifying agents comprise between 0.20 and 0.30% and between 1.00 and 2.50% respectively, of the total formulation by weight.

13. The ink formulation of claim 4 , wherein said first and second emulsifying agents comprise 0.24% and 2.50% respectively, of the total formulation by weight.

14. The ink formulation of claim 4 , wherein the mixing of said pharmaceutically accepted carrier with said preservative is performed at a high speed for approximately 2 minutes.

15. The ink formulation of claim 4 , wherein the pre-wetting of said carbon pigment with said first emulsifying agent and the mixing of said second emulsifying agent with glycerin are performed separately and wherein both the pre-wetting of said carbon pigment with said first emulsifying agent and the mixing of said second emulsifying agent with glycerin are performed using a homogenizer.

16. An ink formulation for use on living tissue, having a total weight, comprising carbon pigment particles, wherein said carbon pigment particles are encapsulated by at least one of lecithin, soy lecithin, polyvinylpyrrolidone (PVP), emulsifying wax, polysorbate 20, or glycerin to form a water-soluble coating around said carbon pigment particles and wherein said encapsulated carbon pigment particles substantially form a dispersion, and not a suspension, in the ink formulation.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2019
From: ENDOCHOICE, INC.
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 049053/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2015
From: STORY, MYTIA V.; STORY, DARLENE P.
To: ENDOCHOICE, INC.
Reel/Frame 034732/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2014
From: STORY, MYTIA V.; STORY, DARLENE P.
To: ENDOCHOICE
Reel/Frame 034164/0098 →